Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission? - Wikidata - wikimedia - TriplyDB

Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission?

Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission?

http://www.wikidata.org/entity/Q47611845

about

Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis.

P2860

Q35142616-BB7680C1-5DA6-4A7D-921E-7ABBB91720A9 Q44477645-CED75F12-FCBD-4EF3-87A0-7A3CA49A5435

P2860

Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission?

http://www.wikidata.org/entity/Q47611845

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission?

@en

Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission?

@nl

type

label

Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission?

@en

Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission?

@nl

prefLabel

Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission?

@en

Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission?

@nl

P1433

Q47611845-D031B584-C3F5-498E-A98C-247C83A90CBC

P1476

Q47611845-8F2AB77A-3AA1-4199-B592-DC214B129765

P2093

Q47611845-01436294-7A12-4D99-8147-5CB7C767F760

Q47611845-DEDE1B74-1856-4E31-8BB6-2174306EB600

P2860

Q47611845-130FA3B8-2C29-4496-A9AF-B6912255AE64

Q47611845-1F3CC198-161C-4126-8F1A-2C4936FBAADD

Q47611845-228EB918-8664-4E6D-8672-2BDC109EACCD

Q47611845-22E74451-A2F2-4D0B-9862-E9B1ED125088

Q47611845-249B568D-7AF8-4C08-AA26-7A73BFF5F887

Q47611845-349BC3A9-37CF-49BE-AF85-539C62DC2A9E

Q47611845-3CF390AD-0D8C-44B6-B37D-8B49640721E0

Q47611845-3D014241-9798-45DF-B3FE-A5EE65B687D6

Q47611845-42428CE6-C7D4-4AFF-A971-A84DDD50690D

Q47611845-4ED9C3A2-878A-4A82-8B08-FAF56C131C25

P2888

Q47611845-4D39A2EB-A000-4B0E-8226-4A2DA162AD9E

P304

Q47611845-251C16A5-044B-4935-B349-1624B30070A1

P31

Q47611845-8FBC2C27-0770-4542-A36C-02B8F8F3831F

P356

Q47611845-619DBA4F-D2BD-4CBC-9C7D-E267158029CD

P407

Q47611845-633042E6-CEDB-4E9E-86FE-C95F777D0C69

P433

Q47611845-3D6E30B5-4986-4F43-A965-19B827B6E7C6

P478

Q47611845-4F00AA87-2271-4ABF-8698-726B87925D72

P577

Q47611845-30E99613-72AB-41D4-9BC8-09832B002A19

P5875

Q47611845-B0ED00DC-B0BC-4E8B-9353-942AD53D4459

P698

Q47611845-9707F078-BFB1-4ACB-BADF-45203FEFF043

P921

Q47611845-11CB6319-B0B7-460D-A03D-2E286E67C167

Q47611845-905D5EBF-384D-4814-80A2-DABDB52746AD

P356

P1433

Bone Marrow Transplantation

P1476

Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission?

@en

P2093

Chakrabarti S

http://www.w3.org/2001/XMLSchema#string

Marks DI

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

T-cell co-signalling molecules in graft-versus-host disease.

HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand.

Mesenchymal stem cells: heading into the clinic.

Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation.

Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.

Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?

The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.

P2888

P304

1039-1050

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BMT.1704281

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9001088

http://www.w3.org/2001/XMLSchema#string

P698

14625574

http://www.w3.org/2001/XMLSchema#string

P921